Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

Title
Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)
Authors
Keywords
-
Journal
Science Signaling
Volume 11, Issue 551, Pages eaat9773
Publisher
American Association for the Advancement of Science (AAAS)
Online
2018-10-10
DOI
10.1126/scisignal.aat9773

Ask authors/readers for more resources

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation